Ben Doranz is President and CEO of Integral Molecular. Dr. Doranz co-founded the company in 2001 and has led all aspects of the company’s growth since its inception, bringing 6 different technologies from research to market and growing the company into a profitable commercial entity. He is an inventor on 10 of the company’s patents, the principal investigator on over 30 NIH grants, and an author on over 100 publications, including articles published in Cell, Science, and Nature.

Dr. Doranz is an established life science entrepreneur previously responsible for directing the biotechnology program at the Science Center’s business incubator in Philadelphia and helping create startups at the technology transfer office at the University of Pennsylvania. Dr. Doranz earned a Ph.D. in Cellular and Molecular Biology from the University of Pennsylvania where he led the discovery of the coreceptor for HIV (CCR5), an MBA at Wharton where he co-founded the Penn Biotech Group (PBG) and won the Wharton business plan competition, and a B.A. at Cornell University. In 2024 he was named CEO of the year in Pennsylvania by Life Sciences PA.